Press release
Primary Ciliary Dyskinesia Clinical Trials, Companies, Therapies, Pipeline | Parion Sciences, ReCode Therapeutics, Translate Bio, Santhera Pharmaceuticals, ethris GmbH
Primary Ciliary Dyskinesia Clinical Trials
Primary Ciliary Dyskinesia Pipeline constitutes 4+ key companies continuously working towards developing 4+ Primary Ciliary Dyskinesia treatment therapies, analyzes DelveInsight.
Primary Ciliary Dyskinesia Overview:
Primary ciliary dyskinesia (PCD) is an inherited autosomal recessive disorder that affects the function of tiny, hair-like structures called cilia in the respiratory tract. Dysfunctional cilia impair the clearance of mucus from the lungs, paranasal sinuses, and middle ears, resulting in recurrent respiratory infections as bacteria and irritants become trapped. Symptoms often appear shortly after birth and can include persistent coughing, choking, gagging, and neonatal respiratory distress such as lung atelectasis. People with PCD commonly experience chronic infections in the lungs, sinuses, and middle ears, along with excessive mucus production, persistent coughing, and hearing loss.
Diagnosis is typically confirmed through a lung or sinus biopsy or genetic testing, with ciliary structural abnormalities detectable via electron microscopy. Treatment aims to maintain lung function through airway clearance therapies, including regular cleaning of the sinuses and ear canals. Additional management approaches may involve antibiotics, bronchodilators, steroids, and mucolytic agents to relieve symptoms and prevent complications.
Request for a detailed insights report on Primary Ciliary Dyskinesia pipeline insights [https://www.delveinsight.com/report-store/primary-ciliary-dyskinesia-pcd-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
"Primary Ciliary Dyskinesia Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Primary Ciliary Dyskinesia Therapeutics Market.
Key Takeaways from the Primary Ciliary Dyskinesia Pipeline Report
*
DelveInsight's Primary Ciliary Dyskinesia (PCD) pipeline report highlights an active landscape, with over four companies developing more than four investigational therapies for PCD treatment.
*
Key players in this space include Parion Sciences, ReCode Therapeutics, Translate Bio, Santhera Pharmaceuticals, ethris GmbH, and others, all working to advance new treatment options and improve the therapeutic landscape. Promising pipeline candidates in various stages of development include P 1037, among others.
*
A notable development is ReCode Therapeutics' investigational therapy, RCT1100. In June 2024, the FDA granted Orphan Drug Designation to RCT1100, recognizing its potential to address an unmet medical need. RCT1100 is an inhaled mRNA therapy designed to deliver DNAI1 mRNA to airway cells, aiming to restore normal ciliary function by correcting mutations in the DNAI1 gene, which account for roughly 7% of PCD cases. Preclinical studies have shown that RCT1100 promotes DNAI1 protein production and improves ciliary function in relevant models. ReCode is currently conducting a Phase 1 open-label trial to evaluate the safety and tolerability of single ascending doses of inhaled RCT1100 in patients with PCD caused by pathogenic DNAI1 mutations.
Primary Ciliary Dyskinesia Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Primary Ciliary Dyskinesia Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Primary Ciliary Dyskinesia treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Primary Ciliary Dyskinesia market.
Download our free sample page report on Primary Ciliary Dyskinesia pipeline insights [https://www.delveinsight.com/sample-request/primary-ciliary-dyskinesia-pcd-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Primary Ciliary Dyskinesia Emerging Drugs
*
P 1037: Parion Sciences
Primary Ciliary Dyskinesia Companies
Over four leading companies are actively working on therapies for Primary Ciliary Dyskinesia, with Parion Sciences having the most advanced candidates currently in Phase II clinical trials.
DelveInsight's report covers around 4+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Primary Ciliary Dyskinesia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Primary Ciliary Dyskinesia Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Primary Ciliary Dyskinesia Therapies and Key Companies: Primary Ciliary Dyskinesia Clinical Trials and advancements [https://www.delveinsight.com/report-store/primary-ciliary-dyskinesia-pcd-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Primary Ciliary Dyskinesia Pipeline Therapeutic Assessment
- Primary Ciliary Dyskinesia Assessment by Product Type
- Primary Ciliary Dyskinesia By Stage
- Primary Ciliary Dyskinesia Assessment by Route of Administration
- Primary Ciliary Dyskinesia Assessment by Molecule Type
Download Primary Ciliary Dyskinesia Sample report to know in detail about the Primary Ciliary Dyskinesia treatment market @ Primary Ciliary Dyskinesia Therapeutic Assessment [https://www.delveinsight.com/sample-request/primary-ciliary-dyskinesia-pcd-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Primary Ciliary Dyskinesia Current Treatment Patterns
4. Primary Ciliary Dyskinesia - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Primary Ciliary Dyskinesia Late-Stage Products (Phase-III)
7. Primary Ciliary Dyskinesia Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Primary Ciliary Dyskinesia Discontinued Products
13. Primary Ciliary Dyskinesia Product Profiles
14. Primary Ciliary Dyskinesia Key Companies
15. Primary Ciliary Dyskinesia Key Products
16. Dormant and Discontinued Products
17. Primary Ciliary Dyskinesia Unmet Needs
18. Primary Ciliary Dyskinesia Future Perspectives
19. Primary Ciliary Dyskinesia Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Primary Ciliary Dyskinesia Pipeline Reports Offerings [https://www.delveinsight.com/report-store/primary-ciliary-dyskinesia-pcd-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=primary-ciliary-dyskinesia-clinical-trials-companies-therapies-pipeline-parion-sciences-recode-therapeutics-translate-bio-santhera-pharmaceuticals-ethris-gmbh]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Ciliary Dyskinesia Clinical Trials, Companies, Therapies, Pipeline | Parion Sciences, ReCode Therapeutics, Translate Bio, Santhera Pharmaceuticals, ethris GmbH here
News-ID: 4155058 • Views: …
More Releases from ABNewswire
PCSK9 Inhibitors Market Landscape: Clinical Pipeline, Competitive Strategies, an …
DelveInsight's PCSK9 Inhibitors Market Report highlights strong growth potential, with the 7MM market projected to expand significantly by 2034 from USD 2B in 2023. The U.S. leads with ~USD 900M. Key players include Sanofi, Regeneron, Amgen, AstraZeneca, LIB Therapeutics, Merck, Novartis, Alnylam, Aqur Biosciences, and CiVi Biopharma. Current leaders PRALUENT and REPATHA dominate, while pipeline assets like LIB003 and MK-0616 signal the next wave of innovation.
DelveInsight's comprehensive [https://www.delveinsight.com/report-store/pcsk9-inhibitors-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report, provides…
Bronchiectasis Treatment Landscape: FDA Approves BRINSUPRI, First Disease-Modify …
DelveInsight Business Research's latest report highlights the transformative impact of the FDA's approval of BRINSUPRI (brensocatib) by Insmed Incorporated (NASDAQ: INSM). This landmark approval marks the first disease-specific therapy for bronchiectasis, offering new hope for over one million patients suffering from this chronic, progressive lung disease characterized by irreversible bronchial airway dilation and impaired mucociliary function.
Key Bronchiectasis Market Highlights
*
BRINSUPRI's approval is expected to be a key bronchiectasis market driver,…
Recurrent Respiratory Papillomatosis Treatment Landscape: FDA Approves PAPZIMEOS …
DelveInsight Business Research's latest report highlights the transformative impact of the FDA's approval of PAPZIMEOS (zopapogene imadenovec-drba) by Precigen, Inc. (NASDAQ: PGEN). This landmark approval marks the first FDA-approved therapy for recurrent respiratory papillomatosis in history, offering unprecedented hope for thousands of patients suffering from this rare and debilitating condition caused by human papillomavirus infection.
Key Recurrent Respiratory Papillomatosis Market Highlights
*
PAPZIMEOS approval represents a paradigm shift in the recurrent respiratory…
Fibromyalgia Treatment Landscape: FDA Approves TONMYA, First New Therapy in 15 Y …
DelveInsight Business Research's latest report highlights the transformative impact of the FDA's approval of TONMYA (cyclobenzaprine HCl sublingual tablets) by Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP). This landmark approval marks the first new fibromyalgia treatment approved by the FDA in more than 15 years, offering new hope for millions of patients suffering from this debilitating chronic pain condition.
Key Fibromyalgia Market Highlights
*
TONMYA's approval is expected to be a key driver…
More Releases for Primary
Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as…
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and…
Primary Biliary Cholangitis Treatment Market
Primary Biliary Cholangitis Treatment Market
Global Primary Biliary Cholangitis Treatment Market Expected to Reach US$ YY Million by 2030, Growing at a CAGR of YY%: Market Insights and Dynamics
The Global Primary Biliary Cholangitis Treatment Market, which reached US$ YY billion in 2022, is anticipated to achieve US$ YY million by 2030, exhibiting a robust CAGR of YY% during the forecast period from 2024 to 2031.
Primary Biliary Cholangitis (PBC), formerly known as…
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit
Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy
Email primaryhealthcare@pulsusgathering.org
On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity…
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5%
Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across…
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include:
1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk…
